Gilead Sciences Inc is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines in areas of unmet medical need, particularly in infectious diseases, oncology, and inflammatory diseases. The company's mission is to advance the care of patients worldwide through groundbreaking research and development. Gilead Sciences Inc employs a strategy focused on leveraging its scientific expertise and robust pipeline to deliver transformative therapies, while also fostering collaborations and partnerships to enhance its operational capabilities and expand access to its life-saving treatments globally.

GILEAD SCIENCES INC

Gilead Sciences Inc. (GILD) has recently reported strong financial performance, positioning itself favorably in the pharmaceutical market as of February 15, 2025. For the full year 2024, the company's revenue reached $28.8 billion, with HIV treatment Biktarvy alone generating $13.4 billion—a notable 13% increase from the previous year. This solid...

Gilead Sciences Reports Strong Q4 Earnings and Impressive Sales Growth for HIV Treatment Amid Market Challenges

Gilead Sciences has demonstrated remarkable financial strength with a 2024 revenue of $28.8 billion, driven by a 13% increase in Biktarvy sales. As the company prepares to launch lenacapavir, could this innovative approach to HIV prevention redefine market dynamics?